Skba Capital Management LLC trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,400 shares of the medical instruments supplier’s stock after selling 300 shares during the quarter. Skba Capital Management LLC’s holdings in Becton, Dickinson and were worth $273,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BDX. BlackRock Inc. grew its position in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its position in Becton, Dickinson and by 49,944.3% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 863,264 shares of the medical instruments supplier’s stock valued at $168,431,000 after purchasing an additional 861,539 shares during the last quarter. Vanguard Group Inc. grew its position in Becton, Dickinson and by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after purchasing an additional 796,034 shares during the last quarter. Principal Financial Group Inc. grew its position in Becton, Dickinson and by 185.3% during the 2nd quarter. Principal Financial Group Inc. now owns 909,235 shares of the medical instruments supplier’s stock valued at $177,401,000 after purchasing an additional 590,494 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Becton, Dickinson and during the 1st quarter valued at about $101,993,000. 87.12% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 198.08 on Friday. The stock has a market cap of $45.08 billion, a P/E ratio of 57.36 and a beta of 1.05. The stock’s 50 day moving average is $197.22 and its 200-day moving average is $192.46. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were issued a dividend of $0.73 per share. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/08/becton-dickinson-and-company-bdx-position-reduced-by-skba-capital-management-llc.html.

Several analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Becton, Dickinson and in a research report on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective on the stock. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reissued a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Finally, Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $200.93.

In related news, insider Gary M. Cohen sold 15,044 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the sale, the insider now owns 95,270 shares in the company, valued at $19,094,966.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 75,904 shares of company stock worth $15,242,688. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.